The corporate aims to increase its investment decision in biotechnology and biosimilars, focusing on an approximate current market worth of USD 25 billion in India by 2025. Wockhardt's efforts to scale up manufacturing capabilities are evident, with options to reinforce output potential by thirty% more than the next two many https://advicebookmarks.com/story27619657/fascination-about-codeine-syrup